Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(13%)

Phase Distribution

Ph not_applicable

13%

Ph phase_4

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 4Post-market surveillance

2(66.7%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(2)

Other(2)

Detailed Status

Completed4

unknown2

Withdrawn1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 4

Trials by Phase

Phase 42 (66.7%)

N/A1 (33.3%)

Trials by Status

completed450%

unknown225%

withdrawn113%

terminated113%

Recent Activity

0 active trials

Showing 5 of 8

completed

Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-2)

NCT05481801

unknown

Post Covid-19 Vaccination Development or Flare of ARD

NCT05160428

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT05222139

Monitoring COVID-19 Vaccination Response in Fragile Populations

PREPARE-iVAC Trial

Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)

Terminated

NCT05481801

Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-2)

Completed

NCT05160428

Post Covid-19 Vaccination Development or Flare of ARD

Unknown

NCT04944134

COVID-19 Antibody Levels After Vaccines

Completed

NCT05075499Not Applicable

Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab

Unknown

NCT04818736Phase 4

COVID-19 Vaccine For Indirect Protection

Withdrawn

All 8 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 8